Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30767633 | 0.91 | CHRM5 (0.43) | CHRM5CYP1A2MAPTRAB9AL3MBTL1 | |
| SCHEMBL2056330 | 0.86 | SMN1; SMN2 (0.54) | CHRM5CYP1A2MAPTRAB9AL3MBTL1 | |
| SCHEMBL1550145 | 0.85 | CHRM5 (0.46) | CHRM5CYP1A2MAPTRAB9AL3MBTL1 | |
| SCHEMBL19531531 | 0.85 | CHRM5 (0.46) | CHRM5CYP1A2MAPTRAB9AL3MBTL1 | |
| SCHEMBL8515356 | 0.82 | MAPT (0.57) | CHRM5CYP1A2MAPTRAB9AL3MBTL1 | |
| SCHEMBL3602312 | 0.80 | ALDH1A1 (0.47) | CHRM5SCN5AALDH1A1 | |
| SCHEMBL21034957 | 0.80 | KDM1A (0.47) | CHRM5CYP1A2MAPTRAB9AL3MBTL1 | |
| SCHEMBL31374887 | 0.80 | CHRM5 (0.44) | CHRM5CYP1A2MAPTRAB9AL3MBTL1 | |
| SCHEMBL1550000 | 0.80 | CYP11B1 (0.49) | RAB9AL3MBTL1FNTAPGGT1BNPC1 | |
| Hydrochloric Acid SCHEMBL31375590 | 0.78 | CYP11B1 (0.48) | RAB9AL3MBTL1FNTAPGGT1BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1875002-B | Phenyl derivatives as PPAR agonists | HOFFMANN LA ROCHE | 2011-08-03 | — | — | CN | disclosed |
| EP-2314576-A1 | Phenyl derivatives as PPAR agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| CN-100509802-C | Heteroaryl deravatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | CN | disclosed |
| US-7429605-B2 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-30 | — | — | US | disclosed |
| CN-101213186-A | Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | CN | disclosed |
| EP-1912969-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017169-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032530-A1 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| CN-1878768-A | heteroaryl derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2006-12-13 | — | — | CN | disclosed |
| CN-1875002-A | Phenyl derivatives as PPAR agonists | HOFFMANN LA ROCHE (CH) | 2006-12-06 | — | — | CN | disclosed |
| US-7115611-B2 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1682508-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| EP-1682535-A1 | HETEROARYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| US-6995263-B2 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-02-07 | — | — | US | disclosed |
| WO-2005049606-A1 | HETEROARYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049573-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032530-A1 | Phenylpyridine derivatives | CYP3A5, QDPR, DPYD | CHRM5 1018/4885CYP1A2 19/4885MAPT 2093/4885 |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | CHRM5 194/4885CYP1A2 94/4885MAPT 2957/4885 |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | CHRM5 256/4885CYP1A2 233/4885MAPT 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.